Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400398 · ClinicalTrials.gov registry record
Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients
A clinical trial, sponsored by Andrew Hendifar, MD.
- Completed
- Registry status
- 30
- Enrollment target
NCT02400398: Completed study, sponsored by Andrew Hendifar, MD.
NCT02400398 is a clinical trial that has completed, run by Andrew Hendifar, MD. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02400398 has completed, sponsored by Andrew Hendifar, MD.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Eligible patients will have a diagnosis of both pancreatic adenocarcinoma and cachexia defined as greater than 5% unintentional weight loss within 6 months prior to screening visit. Patients must be greater than 18 years of age; and have greater than 3 months life expectancy. This study will observe a standard of care intervention (tube feeding) for potential benefit. Peptamen will be administered through a jejunal or a gastrojejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered daily for the duration of the protocol.
Interventions
- OTHER Tube feeding
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2020-05-15 |
What the finished NCT02400398 record still lists
NCT02400398 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tube feeding is the first listed.
NCT02400398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02400398 about?
NCT02400398 is a clinical study titled "Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients". Eligible patients will have a diagnosis of both pancreatic adenocarcinoma and cachexia defined as greater than 5% unintentional weight loss within 6 months prior to screening visit. Patients must be greater than 18 years of age; and have greater than 3 months life expectancy. This study will observ...
What is the current status of trial NCT02400398?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2015-04-27. Estimated completion is 2020-05-15.
What interventions are being tested in trial NCT02400398?
The interventions under investigation include: Tube feeding (OTHER).
Who is sponsoring clinical trial NCT02400398?
This trial is sponsored by Andrew Hendifar, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI